ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
New data presented at ASN indicates SGLT2 inhibitors improve survival and cognitive function for elderly patients with chronic kidney disease.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Medical research presented at the American Society of Nephrology (ASN) indicates that SGLT2 inhibitors provide significant benefits for elderly patients suffering from chronic kidney disease (CKD). According to reporting from Medical Xpress and the South Florida Times, these kidney drugs are linked to longer survival rates, with positive outcomes observed even in patients over the age of 80. The findings suggest that this specific class of medication offers a viable therapeutic path for a demographic that often faces complex treatment challenges due to advanced age and comorbid renal conditions. Coverage from Medscape and DocWireNews emphasizes the multifaceted nature of these benefits. Medscape specifically notes that the administration of SGLT2 inhibitors correlates with improvements in both mortality rates and cognitive function among older CKD patients.
Furthermore, DocWireNews highlights that these inhibitors confer cardiorenal protection, suggesting that the benefits extend beyond the kidneys to include the cardiovascular system. The breadth of these findings across different medical reporting outlets underscores a shift in how these drugs are viewed for geriatric populations. To understand why these findings matter, it is necessary to look at the intersection of age and chronic kidney disease. The South Florida Times emphasizes the importance of survival data for those aged 80 and above, a group where treatment efficacy can vary significantly. By demonstrating that SGLT2 inhibitors can improve longevity and cognitive health, the research addresses a critical gap in the management of elderly patients who require cardiorenal protection to maintain their quality of life and overall survival.
Future attention will likely focus on the broader application of these cardiorenal protections within clinical settings for the elderly. Based on the current reports from ASN, the medical community is monitoring how the improvements in cognition and mortality translate into long-term patient care. As highlighted by Medscape and Medical Xpress, the core of the current trend is the validation of SGLT2 inhibitors as a beneficial intervention for elderly patients with CKD, regardless of their advanced age.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 12d ago.
Quick answers
Which patient group benefited from SGLT2 inhibitors according to the ASN data?
Elderly patients with chronic kidney disease, including those over the age of 80.
What specific benefits were noted by Medscape?
Medscape reported benefits regarding both mortality and cognition in older CKD patients.
What is the nature of the protection provided by these inhibitors according to DocWireNews?
DocWireNews states that SGLT2 inhibitors confer cardiorenal protection.
Coverage (4)
- SGLT2i Benefit Mortality, Cognition in Older CKD Patients Medscape · 14d ago
- SGLT2 Inhibitors Confer Cardiorenal Protection DocWireNews · 14d ago
- Kidney drugs linked to longer survival even after age 80 South Florida Times · 14d ago
- ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors Medical Xpress · 14d ago
Topics
Related trends
Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.
A Simple Diet Change Could Transform Kidney Disease Treatment, 10-Year Study Finds
A ten-year study links fruit and vegetable consumption to reduced hospitalizations for kidney patients.
Study finds possibly problematic drug combos being prescribed to older adults
A Canadian study warns that common drug combinations are triggering harmful prescribing cascades in older adults, risking their health and independence.
Inappropriate Prescribing Cascades Put Older Adults at Risk
Recent coverage examines inappropriate prescribing cascades where older adults receive new medications to treat side effects.
If You’ve Noticed Your Balance Getting Worse With Age, Experts Say These Solutions Can Help
Health publications and senior care organizations are highlighting targeted solutions to help older adults improve declining balance and reduce fall risks.
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.